level or effect of alfentanil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.alfuzosindexamethasone will decrease the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.alosetrondexamethasone will decrease the level or effect of alosetron by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.ambrisentandexamethasone will decrease the level or effect of ambrisentan by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.amitriptylinedexamethasone will decrease the level or effect of amitriptyline by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.amlodipinedexamethasone will decrease the level or effect of amlodipine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.amphotericin B deoxycholateamphotericin B deoxycholate, dexamethasone. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Potential for hypokalemia.anastrozoleanastrozole will increase the level or effect of dexamethasone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.armodafinildexamethasone will decrease the level or effect of armodafinil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.aspirindexamethasone decreases levels of aspirin by increasing renal clearance. Minor/Significance Unknown.aspirin rectaldexamethasone decreases levels of aspirin rectal by increasing renal clearance. Minor/Significance Unknown.aspirin/citric acid/sodium bicarbonatedexamethasone decreases levels of aspirin/citric acid/sodium bicarbonate by increasing renal clearance. Minor/Significance Unknown.atazanavirdexamethasone will decrease the level or effect of atazanavir by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.balsalazidedexamethasone decreases levels of balsalazide by increasing renal clearance. Minor/Significance Unknown.bendroflumethiazidedexamethasone, bendroflumethiazide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypokalemia, especially with strong glucocorticoid activity.bosentandexamethasone will decrease the level or effect of bosentan by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.bumetanidedexamethasone, bumetanide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypokalemia, especially with strong glucocorticoid activity.calcium acetatedexamethasone decreases levels of calcium acetate by increasing elimination. Minor/Significance Unknown.calcium carbonatedexamethasone decreases levels of calcium carbonate by increasing elimination. Minor/Significance Unknown.calcium chloridedexamethasone decreases levels of calcium chloride by increasing elimination. Minor/Significance Unknown.calcium citratedexamethasone decreases levels of calcium citrate by increasing elimination. Minor/Significance Unknown.calcium gluconatedexamethasone decreases levels of calcium gluconate by increasing elimination. Minor/Significance Unknown.caspofungindexamethasone decreases levels of caspofungin by increasing metabolism. Minor/Significance Unknown.cevimelinedexamethasone will decrease the level or effect of cevimeline by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.chlorothiazidedexamethasone, chlorothiazide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypokalemia, especially with strong glucocorticoid activity.chlorpropamidedexamethasone decreases effects of chlorpropamide by pharmacodynamic antagonism. Minor/Significance Unknown.chlorthalidonedexamethasone, chlorthalidone. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypokalemia, especially with strong glucocorticoid activity.choline magnesium trisalicylatedexamethasone decreases levels of choline magnesium trisalicylate by increasing renal clearance. Minor/Significance Unknown.chromiumdexamethasone decreases levels of chromium by increasing renal clearance. Minor/Significance Unknown.clarithromycindexamethasone will decrease the level or effect of clarithromycin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.clomipraminedexamethasone will decrease the level or effect of clomipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.colestipolcolestipol decreases levels of dexamethasone by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.cyclopenthiazidedexamethasone, cyclopenthiazide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypokalemia, especially with strong glucocorticoid activity.cyclophosphamidecyclophosphamide will increase the level or effect of dexamethasone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.danazoldanazol, dexamethasone. Either increases effects of the other by pharmacodynamic synergism. Minor/Significance Unknown. May enhance edema formation.dapsonedexamethasone will decrease the level or effect of dapsone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.diflunisaldexamethasone decreases levels of diflunisal by increasing renal clearance. Minor/Significance Unknown.disopyramidedexamethasone will decrease the level or effect of disopyramide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.docetaxeldexamethasone will decrease the level or effect of docetaxel by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.donepezildexamethasone will decrease the level or effect of donepezil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.dutasteridedexamethasone will decrease the level or effect of dutasteride by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.efavirenzdexamethasone will decrease the level or effect of efavirenz by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.eplerenonedexamethasone will decrease the level or effect of eplerenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.esomeprazoledexamethasone will decrease the level or effect of esomeprazole by increasing metabolism. Minor/Significance Unknown.ethacrynic aciddexamethasone, ethacrynic acid. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypokalemia, especially with strong glucocorticoid activity.eucalyptusdexamethasone will decrease the level or effect of eucalyptus by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.feverfewdexamethasone decreases effects of feverfew by pharmacodynamic antagonism. Minor/Significance Unknown.finasteridedexamethasone will decrease the level or effect of finasteride by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.fluoxymesteronefluoxymesterone, dexamethasone. Either increases effects of the other by pharmacodynamic synergism. Minor/Significance Unknown. May enhance edema formation.furosemidedexamethasone, furosemide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypokalemia, especially with strong glucocorticoid activity.galantaminedexamethasone will decrease the level or effect of galantamine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.glimepiridedexamethasone decreases effects of glimepiride by pharmacodynamic antagonism. Minor/Significance Unknown.glipizidedexamethasone decreases effects of glipizide by pharmacodynamic antagonism. Minor/Significance Unknown.glyburidedexamethasone decreases effects of glyburide by pharmacodynamic antagonism. Minor/Significance Unknown.hydrochlorothiazidedexamethasone, hydrochlorothiazide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypokalemia, especially with strong glucocorticoid activity.imatinibdexamethasone will decrease the level or effect of imatinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.imipraminedexamethasone will decrease the level or effect of imipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.indapamidedexamethasone, indapamide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypokalemia, especially with strong glucocorticoid activity.insulin aspartdexamethasone decreases effects of insulin aspart by pharmacodynamic antagonism. Minor/Significance Unknown.insulin detemirdexamethasone decreases effects of insulin detemir by pharmacodynamic antagonism. Minor/Significance Unknown.insulin glarginedexamethasone decreases effects of insulin glargine by pharmacodynamic antagonism. Minor/Significance Unknown.insulin glulisinedexamethasone decreases effects of insulin glulisine by pharmacodynamic antagonism. Minor/Significance Unknown.insulin lisprodexamethasone decreases effects of insulin lispro by pharmacodynamic antagonism. Minor/Significance Unknown.insulin NPHdexamethasone decreases effects of insulin NPH by pharmacodynamic antagonism. Minor/Significance Unknown.insulin regular humandexamethasone decreases effects of insulin regular human by pharmacodynamic antagonism. Minor/Significance Unknown.isoniaziddexamethasone decreases effects of isoniazid by unknown mechanism. Minor/Significance Unknown.isradipinedexamethasone will decrease the level or effect of isradipine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.ketoconazoledexamethasone will decrease the level or effect of ketoconazole by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.lansoprazoledexamethasone will decrease the level or effect of lansoprazole by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.levoketoconazoledexamethasone will decrease the level or effect of levoketoconazole by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.mesalaminedexamethasone decreases levels of mesalamine by increasing renal clearance. Minor/Significance Unknown.mesterolonemesterolone, dexamethasone. Either increases effects of the other by pharmacodynamic synergism. Minor/Significance Unknown. May enhance edema formation.metformindexamethasone decreases effects of metformin by pharmacodynamic antagonism. Minor/Significance Unknown.methyclothiazidedexamethasone, methyclothiazide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypokalemia, especially with strong glucocorticoid activity.methyltestosteronemethyltestosterone, dexamethasone. Either increases effects of the other by pharmacodynamic synergism. Minor/Significance Unknown. May enhance edema formation.metolazonedexamethasone, metolazone. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypokalemia, especially with strong glucocorticoid activity.metyraponedexamethasone decreases effects of metyrapone by unspecified interaction mechanism. Minor/Significance Unknown.miglitoldexamethasone decreases effects of miglitol by pharmacodynamic antagonism. Minor/Significance Unknown.montelukastdexamethasone will decrease the level or effect of montelukast by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.nateglinidedexamethasone decreases effects of nateglinide by pharmacodynamic antagonism. Minor/Significance Unknown.nimodipinedexamethasone will decrease the level or effect of nimodipine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.nitrendipinedexamethasone will decrease the level or effect of nitrendipine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.omeprazoledexamethasone will decrease the level or effect of omeprazole by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.oxandroloneoxandrolone, dexamethasone. Either increases effects of the other by pharmacodynamic synergism. Minor/Significance Unknown. May enhance edema formation.oxybutynindexamethasone will decrease the level or effect of oxybutynin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.oxymetholoneoxymetholone, dexamethasone. Either increases effects of the other by pharmacodynamic synergism. Minor/Significance Unknown. May enhance edema formation.paclitaxeldexamethasone will decrease the level or effect of paclitaxel by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.paclitaxel protein bounddexamethasone will decrease the level or effect of paclitaxel protein bound by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.pantoprazoledexamethasone will decrease the level or effect of pantoprazole by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.parecoxibdexamethasone will decrease the level or effect of parecoxib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.pimozidedexamethasone will decrease the level or effect of pimozide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.pioglitazonedexamethasone will decrease the level or effect of pioglitazone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.dexamethasone decreases effects of pioglitazone by pharmacodynamic antagonism. Minor/Significance Unknown.porfimerdexamethasone decreases levels of porfimer by unspecified interaction mechanism. Minor/Significance Unknown.propafenonedexamethasone will decrease the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.quininedexamethasone will decrease the level or effect of quinine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.rabeprazoledexamethasone will decrease the level or effect of rabeprazole by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.ramelteondexamethasone will decrease the level or effect of ramelteon by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.repaglinidedexamethasone decreases effects of repaglinide by pharmacodynamic antagonism. Minor/Significance Unknown.rosiglitazonedexamethasone decreases effects of rosiglitazone by pharmacodynamic antagonism. Minor/Significance Unknown.salicylates (non-asa)dexamethasone decreases levels of salicylates (non-asa) by increasing renal clearance. Minor/Significance Unknown.salsalatedexamethasone decreases levels of salsalate by increasing renal clearance. Minor/Significance Unknown.sargramostimdexamethasone increases effects of sargramostim by pharmacodynamic synergism. Minor/Significance Unknown.saxagliptindexamethasone will decrease the level or effect of saxagliptin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.dexamethasone decreases effects of saxagliptin by pharmacodynamic antagonism. Minor/Significance Unknown.sitagliptindexamethasone decreases effects of sitagliptin by pharmacodynamic antagonism. Minor/Significance Unknown.sufentanildexamethasone will decrease the level or effect of sufentanil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.sulfasalazinedexamethasone decreases levels of sulfasalazine by increasing renal clearance. Minor/Significance Unknown.tacrolimusdexamethasone, tacrolimus. Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown.testosteronetestosterone, dexamethasone. Either increases effects of the other by pharmacodynamic synergism. Minor/Significance Unknown. May enhance edema formation.testosterone buccal systemtestosterone buccal system, dexamethasone. Either increases effects of the other by pharmacodynamic synergism. Minor/Significance Unknown. May enhance edema formation.testosterone topicaltestosterone topical, dexamethasone. Either increases effects of the other by pharmacodynamic synergism. Minor/Significance Unknown. May enhance edema formation.tolazamidedexamethasone decreases effects of tolazamide by pharmacodynamic antagonism. Minor/Significance Unknown.tolbutamidedexamethasone decreases effects of tolbutamide by pharmacodynamic antagonism. Minor/Significance Unknown.torsemidedexamethasone, torsemide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypokalemia, especially with strong glucocorticoid activity.vildagliptindexamethasone decreases effects of vildagliptin by pharmacodynamic antagonism. Minor/Significance Unknown.vinblastinedexamethasone will decrease the level or effect of vinblastine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.vincristinedexamethasone will decrease the level or effect of vincristine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.vincristine liposomaldexamethasone will decrease the level or effect of vincristine liposomal by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.vinorelbinedexamethasone will decrease the level or effect of vinorelbine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.willow barkdexamethasone decreases levels of willow bark by increasing renal clearance. Minor/Significance Unknown.zaleplondexamethasone will decrease the level or effect of zaleplon by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.ziprasidonedexamethasone will decrease the level or effect of ziprasidone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.zolpidemdexamethasone will decrease the level or effect of zolpidem by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.zonisamidedexamethasone will decrease the level or effect of zonisamide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.abametapirSerious - Use Alternative (1)abametapir will increase the level or effect of dexamethasone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. For 2 weeks after abametapir application, avoid taking drugs that are CYP3A4 substrates. If not feasible, avoid use of abametapir.abemaciclibSerious - Use Alternative (1)dexamethasone will decrease the level or effect of abemaciclib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Coadministration of abemaciclib with strong CYP3A4 inducers reduces plasma concentration of abemaciclib and its metabolites.abirateroneMonitor Closely (1)dexamethasone decreases levels of abiraterone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Avoid coadministration of abiraterone with strong CYP3A4 inducers; if a strong CYP3A4 inducer must be used, increase abiraterone dosage frequency from once daily to twice daily.acalabrutinibSerious - Use Alternative (1)dexamethasone will decrease the level or effect of acalabrutinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of acalabrutinib with strong CYP3A inducers. If a strong CYP3A inducer must be used, increase acalabrutinib dose to 200 mg twice daily.acarboseMinor (1)dexamethasone decreases effects of acarbose by pharmacodynamic antagonism. Minor/Significance Unknown.aceclofenacMonitor Closely (1)aceclofenac, dexamethasone. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of GI ulceration.acemetacinMonitor Closely (1)acemetacin, dexamethasone. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of GI ulceration.acetazolamideMinor (1)acetazolamide will increase the level or effect of dexamethasone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.adenovirus types 4 and 7 live, oralSerious - Use Alternative (1)dexamethasone decreases effects of adenovirus types 4 and 7 live, oral by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Corticosteroids may diminish therapeutic effects of vaccines and increase risk of adverse effects (increased risk of infection). Live-attenuated vaccines should be avoided for at least 3mo after cessation of corticosteroid therapy.albendazoleMinor (1)dexamethasone increases levels of albendazole by unspecified interaction mechanism. Minor/Significance Unknown.albiglutideMonitor Closely (1)dexamethasone decreases effects of albiglutide by pharmacodynamic antagonism. Use Caution/Monitor. Corticosteroids may diminish hypoglycemic effect of antidiabetic agents. Monitor blood glucose levels carefully.